ANI Pharmaceuticals, Inc.

ANIP Healthcare Drug Manufacturers Specialty & Generic

ANI Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $883.4 million, up 43.8% from fiscal 2024. In the quarter to June 2026, revenue grew 25.9%, EPS grew 194.6%, free cash flow fell 22.2% and total debt fell 1.78%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

72.08 0.20 −0.28%
Market cap
$1.7B
P/E
14.9×
Fwd P/E
14.5×
Dividend yield
—
F-score
7/9
Altman Z
2.30
Beneish M
−2.62
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

8.56% 16.34% 18.63% 20.88%
Piotroski F-Score
7 7 8 7
ROA
2.89% 5.66% 6.73% 7.61%
ROIC
5.26% 8.05% 9.10% 11.30%
Return on Tangible Assets
7.94% 14.36% 15.90% 17.56%
Average Days of Receivables
111.51 116.14 100.93 102.40
Free Cash Flow per Share
6.74 7.53 8.74 7.92
Free Cash Flow
135.32 150.90 182.81 167.52
Capital Expenditures
(35.40) (34.32) (25.80) (21.94)
Other line items
Cash ROIC
9.68% 10.39% 12.17% 10.58%
Accounts Receivable Turnover
3.68 3.51 3.88 3.91
Accounts Payable Turnover
4.92 6.31 5.90 6.03
Inventory Turnover
2.18 2.44 2.58 2.75
Average Days of Payables
79.28 66.93 70.30 69.56
Days of Inventory on Hand
166.39 153.00 144.71 134.87
Tax Rate
(0.20) (0.18) (0.21) (0.24)
Research and Development Expense of Revenue
6.78% 5.85% 5.60% 5.10%
Selling, General and Administrative Expense of Revenue
36.85% 35.97% 34.09% 33.19%
Share Based Compensation of Revenue
4.26% 4.29% 4.25% 4.20%
Interest Coverage
3.32 5.54 6.75 9.09
Operating CF/Net income
4.38 2.40 2.28 1.75
Depreciation/Fixed assets
1.60 1.46 1.33 1.17
Capex/Depreciation
(0.35) (0.38) (0.29) (0.26)
Revenue per Share
41.19 44.05 44.17 46.24
Operating CF per Share
8.50 9.24 9.97 8.95
Capex per Share
(1.76) (1.71) (1.23) (1.04)
Capex to Sales
0.04 0.04 0.03 0.02

Fold the line items

Columns are period end dates